AbbVie Inc (NYSE:ABBV)

48.55
Data as of Apr 17
 +0.43 / +0.89%
Today’s Change
40.10
Today|||52-Week Range
54.78
-8.07%
Year-to-Date
3 Reasons the Market Is Down on Gilead Sciences
Apr 18 / MotleyFool.com
Positive Data on AbbVie's HCV Program - Analyst Blog
Apr 14 / Zacks.com
Glaxo Looking into Misconduct Charges - Analyst Blog
Apr 17 / Zacks.com
Is This the Answer to Expensive Hepatitis-C Cures?
Apr 14 / MotleyFool.com
Roche Meets Sales Estimates in Q1 - Analyst Blog
Apr 17 / Zacks.com
Will Johnson & Johnson (JNJ) Miss This Earnings Season? - Analyst Blog
Apr 14 / Zacks.com
Earnings Primer: What's on Deck for Celgene, AbbVie, and Gilead
Apr 17 / MotleyFool.com
Benzinga's Top #PreMarket Losers
Apr 14 / Benzinga
AbbVie Candidate in Pivotal Study - Analyst Blog
Apr 17 / Zacks.com
Abbott Labs Progresses with Absorb - Analyst Blog
Apr 11 / Zacks.com
If This Biotech Drops Much Further I'm Going to Buy It!
Apr 17 / MotleyFool.com
Encouraging Data from Bristol-Myers - Analyst Blog
Apr 11 / Zacks.com
Will Merck & Co. Inc Unseat Biotech's Hottest Drug?
Apr 17 / MotleyFool.com
Merck Shouts "Me, Too!" But Will It Matter?
Apr 11 / MotleyFool.com
Glaxo's Tanzeum Approved in the U.S. - Analyst Blog
Apr 16 / Zacks.com
Today's Biotech Stocks to Watch: AbbVie Inc., Enanta Pharmaceuticals Inc. and Gilead ...
Apr 11 / MotleyFool.com
Is Johnson & Johnson's Dividend Unbeatable?
Apr 16 / MotleyFool.com
Merck Up on Encouraging HCV Data - Analyst Blog
Apr 10 / Zacks.com
Gilead Sciences, Inc. Feeling Sovaldi Pressure From All Sides
Apr 16 / MotleyFool.com
S&P 500 Dividend Aristocrats: Reliably Growing Dividends
Apr 10 / MotleyFool.com
Abbott Labs Tops Earnings, Misses Sales Est - Analyst Blog
Apr 16 / Zacks.com
Stunning Spending Growth Prediction for Hepatitis C
Apr 10 / MotleyFool.com
Bristol-Myers Seeks Approval for HIV Combo Drug - Analyst Blog
Apr 15 / Zacks.com
Today's Biotech Stocks to Watch: Bristol-Myers Squibb, Gilead Sciences and Merck & Co...
Apr 10 / MotleyFool.com
Repros Completes Enrollment for Androxal Study - Analyst Blog
Apr 15 / Zacks.com
Why Enanta Pharmaceuticals, Inc. Should Be on Your Watchlist
Apr 09 / MotleyFool.com
How Much Has Merck Shaken Up the Hepatitis C Race?
Apr 15 / MotleyFool.com
Why Gilead Sciences, AbbVie Inc., and Biogen Idec Are Today's 3 Worst Stocks
Apr 08 / MotleyFool.com
Will Abbott Labs (ABT) Disappoint This Quarter? - Analyst Blog
Apr 15 / Zacks.com
Bristol-Myers Seeks FDA Approval for HCV Candidates - Analyst Blog
Apr 08 / Zacks.com
AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) for Pat...
Apr 15 / Benzinga
FDA Target Date for Gilead's HCV Candidate - Analyst Blog
Apr 08 / Zacks.com
Hard-to-Cure Patients May Benefit from Merck's HCV Drug - Analyst Blog
Apr 14 / Zacks.com
The AACR Annual Meeting May Move These 2 Stocks
Apr 07 / MotleyFool.com
Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings
Apr 14 / Benzinga
 

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.